# Dejan Juric

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dejan-juric/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,573 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 61 |
| i10-index | 183 |
| Last Known Institution | Dana-Farber/Harvard Cancer Center |
| OpenAlex ID | https://openalex.org/A5087308492 |
| ORCID iD | https://orcid.org/0000-0003-2983-7704 |
| Works | 731 |

## Researcher papers

- [Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma](https://scholariq.org/papers/polyclonal-secondary-i-fgfr2-i-mutations-drive-acquired-resistance-to-fgfr/)
- [Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation](https://scholariq.org/papers/clinical-acquired-resistance-to-krasg12c-inhibition-through-a-novel-kras-switch/)
- [PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer](https://scholariq.org/papers/pten-loss-mediates-clinical-cross-resistance-to-cdk4-6-and-pi3k-inhibitors-in/)
- [Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative/)
- [The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer](https://scholariq.org/papers/the-clinical-landscape-of-cell-free-dna-alterations-in-1671-patients-with/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)

## Researcher university

- [Dana-Farber/Harvard Cancer Center](https://scholariq.org/institutions/dana-farber-harvard-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.